Sohn Y H, Kim G W, Huh K, Kim J S
Department of Neurology and the Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
J Neurol Sci. 1998 Jun 11;158(1):83-7. doi: 10.1016/s0022-510x(98)00102-6.
This study was designed to evaluate the contribution of central dopaminergic mechanisms to the P300 event-related potential (P300) abnormality in Parkinson's disease. We measured the P300 in 37 non-demented patients with Parkinson's disease (19 de novo and 18 levodopa-treated) and 15 age-matched healthy volunteers. The P300 measurement was repeated in 14 de novo patients, after 6-12 months levodopa therapy. The severity of parkinsonian symptom was assessed using the UPDRS-motor scale. De novo patients showed prolonged P300 latency compared with levodopa-treated patients, as well as healthy volunteers. The levodopa therapy for 6-12 months significantly shortened the P300 latency and reduced the UPDRS-motor examination score in de novo patients. However, the percent changes in the P300 latency were not correlated with those in the UPDRS-motor examination score. These results indicate that the central dopaminergic mechanisms apart from those responsible for motor symptoms, may contribute to the P300 abnormality in Parkinson's disease.
本研究旨在评估中枢多巴胺能机制对帕金森病中P300事件相关电位（P300）异常的作用。我们测量了37例非痴呆帕金森病患者（19例初发患者和18例接受左旋多巴治疗的患者）以及15名年龄匹配的健康志愿者的P300。14例初发患者在接受6 - 12个月左旋多巴治疗后重复进行P300测量。使用统一帕金森病评定量表运动部分（UPDRS - motor）评估帕金森病症状的严重程度。与接受左旋多巴治疗的患者以及健康志愿者相比，初发患者的P300潜伏期延长。对初发患者进行6 - 12个月的左旋多巴治疗可显著缩短P300潜伏期并降低UPDRS - motor检查评分。然而，P300潜伏期的百分比变化与UPDRS - motor检查评分的变化不相关。这些结果表明，除了负责运动症状的机制外，中枢多巴胺能机制可能导致帕金森病中的P300异常。
